zolpidem has been researched along with Insulin Resistance in 1 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gramaglia, E | 1 |
| Ramella Gigliardi, V | 1 |
| Olivetti, I | 1 |
| Tomelini, M | 1 |
| Belcastro, S | 1 |
| Calvi, E | 1 |
| Dotta, A | 1 |
| Ghigo, E | 1 |
| Benso, A | 1 |
| Broglio, F | 1 |
1 trial available for zolpidem and Insulin Resistance
| Article | Year |
|---|---|
Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects.
Topics: Adult; Azepines; Benzodiazepines; Blood Glucose; Carbohydrate Metabolism; Drug Administration Schedu | 2014 |